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Introduction {#sec006}
============

Childhood/adult onset Pompe disease (AOPD) is a genetic disorder caused by mutations in the *GAA* gene leading to a deficiency of the enzyme acid α-glucosidase\[[@pone.0163493.ref001]\]. This enzyme degrades glycogen inside the lysosomes. Glycogen accumulates in skeletal muscles of AOPD patients leading to a number of pathologic changes producing muscle weakness\[[@pone.0163493.ref002]\]. AOPD patients may have different clinical presentations, such as asymptomatic hyperCKemia, slowly progressive limb girdle weakness and respiratory insufficiency secondary to respiratory muscle weakness\[[@pone.0163493.ref003]\].

Enzyme replacement therapy with alfa-glucosidase (ERT) has changed the natural history of AOPD\[[@pone.0163493.ref004]\]. Published studies show that ERT improves muscle function during the first months of treatment and stabilizes clinical situation over time\[[@pone.0163493.ref005]--[@pone.0163493.ref007]\]. One of the main drawbacks of this treatment is the high cost of the drug per patient and year (more than 250.000\$/year). Considering that the drug stabilizes function but lifelong treatment is needed, health authorities have expressed concern regarding how to measure the effectiveness of treatment and when therapy should be started\[[@pone.0163493.ref008]\]. Clinical guides suggest that muscle MRI could be useful to follow progression of the disease in treated patients or to monitor signs of muscle deterioration in patients with asymptomatic hyperCKemia, anticipating the onset of their treatment\[[@pone.0163493.ref009]--[@pone.0163493.ref011]\].

Muscle MRI is a useful tool to study the structure of skeletal muscles. There are several sequences that analyzes different aspects of muscle \[[@pone.0163493.ref012]\]. T1-weighted (T1w) and 3-point Dixon imaging provide information on fat infiltration in muscle\[[@pone.0163493.ref013], [@pone.0163493.ref014]\]. T1w imaging has been used to identify patterns of muscle fatty infiltration helpful for the diagnosis of muscles diseases\[[@pone.0163493.ref015], [@pone.0163493.ref016]\]. Recent studies have pointed out the utility of 3-point Dixon sequences to quantify the percentage of fatty infiltration in muscles and follow-up patients over a period of time\[[@pone.0163493.ref017], [@pone.0163493.ref018]\]. However it is not yet known whether the degree of muscle fatty infiltration correlates with muscle strength and function in AOPD patients. This question needs to be addressed prior to consider muscle MRI as a surrogate biomarker of disease progression, especially at present, when ERT has changed the natural history of the disease. To tackle this question, we performed a transversal observational study in a large group of AOPD patients comparing muscle function tests with results of T1w and 3-Point Dixon muscle imaging.

Material and Methods {#sec007}
====================

Clinical assessment {#sec008}
-------------------

We are currently conducting a prospective observational study following-up a cohort of 34 genetically confirmed AOPD patients at the Hospital of Sant Pau. This study is registered in the webpage ClinicalTrials.gov with the identifier NCT01914536. All patients provided written informed consent to participate in the study. The study was reviewed and approved by the Ethics Committee at Hospital de la Santa Creu i Sant Pau.

We collected data concerning epidemiological characteristics, general medical background and current clinical status at basal visit. Two physiotherapists evaluated muscle function using the following tests: 6-minutes walking test (6MWT), time to walk 10 meters, time to up-and-go, time to climb up and down 4 steps, and motor function measure-20 items scale (MFM-20). Daily living activities were studied using Activlim test and quality of life was investigated using INQoL and SF-36 questionnaires.

Muscle strength was studied using both Muscle Research Council scale (MRC) and hand-held myometry. Using MRC, which grades muscle strength from 0 (no movement) to 5 (normal strength), we evaluated neck flexion and extension, arm abduction, elbow flexion and extension, finger flexion and extension, hip flexion, extension, adduction and abduction, knee flexion and extension, and foot flexion, extension, inversion, and eversion. Trunk flexion and extension functions, which are not commonly studied using MRC, were analyzed as follows: normal movement: 5 points, ineffective muscle contraction: 3 points, no muscle contraction: 0 points. We defined a MRC total score as the aggregate of MRC scores of every single function analyzed.

Using hand-held myometry we evaluated the following muscle functions: neck flexion, arm abduction, elbow flexion and extension, hip flexion, extension, adduction, and abduction, knee flexion and extension. These studies were performed only on patient's dominant side. A myometry score was defined as the aggregate of scores obtained with the myometer.

We obtained forced vital capacity seated (sFVC), forced vital capacity in a lying position (lFVC), maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) using a conventional spirometry. We performed a blood analysis to all patients to test CK levels before physiotherapy assessment. The normal values of CK in our laboratory are less than 174 U/L.

Muscle MRI {#sec009}
----------

Whole body muscle MRI was performed in a Philips Achieva XR 1.5 Teslas device at Hospital de la Santa Creu i Sant Pau. Axial T1 weighted turbo spin echo images were obtained using the following acquisition parameters TR = 757 ms, TE = 17 ms, thickness = 8 mm, number of slices = 164, FOV = 530 x 530 mm, acquired voxel size = 1.6 x 2.88 mm. 3-point Dixon images were acquired in 3D with the following acquisition parameters: TR/TE = 5.78/1.8, 4 ms, flip angle = 15 degrees, FOV = 520 x 340 x 300 mm, voxel size = 1 x 1x 3 mm of both thighs and FOV = 520 x 320 x 200 mm and voxel size = 1.3 x 1.7 x 5 mm for the lower trunk. Water and fat images were automatically obtained from the Dixon acquisition. The time to obtain all the images was 45 minutes per patient.

Two observers (J.D. and J.L.) quantified fatty muscle infiltration in T1w imaging using the modified version of the Mercuri score published by the group of Dr. Fischer \[[@pone.0163493.ref019]\]:

-   *Normal muscle appearance*: 0 points

-   *Mild*: traces of increased signal intensity on the T1-weighted MR sequences: 1 point

-   *Moderate*: increased T1-weighted signal intensity with beginning confluence in less than 50% of the muscle: 2 points

-   *Severe*: increased T1-weighted signal intensity with beginning confluence in more than 50% of the muscle: 3 points

-   *End-stage appearance*: entire muscle replaced by increased density of connective tissue and fat: 4 points

Each muscle was evaluated at both sides. A complete list of the muscles analyzed can be found in [S1 Materials](#pone.0163493.s002){ref-type="supplementary-material"}. We generated a muscle MRI score that was calculated adding all the values obtained from the muscles analyzed. Its value ranged from 0 (lowest value, all muscles are scored as 0) to 290 (highest value, all muscles are scored as 4).

To analyze 3-point Dixon images we chose five cross-sectional Dixon slices of thighs and lower trunk, in which muscle volume was highest. A complete list of the muscles analyzed can be found in [S1 Materials](#pone.0163493.s002){ref-type="supplementary-material"}. We mapped full cross-section of muscle groups or individual muscles and the fat fractional data were generated.

A single observer (S.F-B) estimated fat content in the muscles using the PRIDE platform (Philips Research Image Development Environment) which enables analysis of Dixon images. In order to calculate the fat fraction, a ROI (Region of Interest) was drawn in both the fat and water images. Fat fraction coefficient was defined as fat⁄(fat+water) where fat and water are the image intensity values over the ROI for the water and fat images respectively.

Statistics {#sec010}
----------

We used Shapiro-Wilk test to confirm that none of our measured variables were normally distributed and we used non-parametric statistic tests for the analysis.

Mann-Whitney U test was used to compare quantitative variables and Chi-square test to compare qualitative variables. To investigate whether there was a correlation between the muscle function scales and MRI findings we used Spearman's rank correlation (coefficient reported as r). We considered the correlation was good if P was lower than 0.05 and r was 0.65 or higher. Hierarchical analysis and graphical representation as a heatmap was performed using R software version 3.1.3 as previously described\[[@pone.0163493.ref020]\]. Statistical studies were performed using SPSS^®^ Statistics software version 21 from IBM^®^. All data acquired from the visits and analysis of the MRIs can be found in the Supplemental Study Data Section.

Results {#sec011}
=======

Clinical description of the cohort {#sec012}
----------------------------------

We included 34 patients with a diagnosis of AOPD ([Table 1](#pone.0163493.t001){ref-type="table"}). Seven patients were considered asymptomatic as they had only hyperCKemia, without any clinical symptom of muscle weakness, while 27 patients were considered symptomatic as they had muscle weakness. HyperCKemia patients were younger than symptomatic ones (21.4 y.o. vs 50.18 y.o, Mann-Whitney U test, p\<0.001) ([Table 2](#pone.0163493.t002){ref-type="table"}).

10.1371/journal.pone.0163493.t001

###### List of patients participating in the study.

![](pone.0163493.t001){#pone.0163493.t001g}

  N    Gender   Age at Study (y)   Phenotype                                                         GAA gene                  CK (U/l)                ERT    Age at ERT (y)   Wheelchair dependent   Ventilation   
  ---- -------- ------------------ ----------------------------------------------------------------- ------------------------- ----------------------- ------ ---------------- ---------------------- ------------- ---
  1    F        50                 Proximal weakness LL + axial                                      IVS1-13T\>G               c.1076-1G\>C            251    Yes              47                     N             N
  2    F        48                 Proximal weakness UL and LL + axial + respiratory insufficiency   IVS1-13T\>G IVS1-13T\>G   c.2173C\>T              779    Yes              39                     Y             Y
  3    F        26                 HyperCKemia                                                       IVS1-13T\>G               c.1889-1G\>A            779    No               \-                     N             N
  4    F        63                 Proximal weakness LL + axial                                      IVS1-13T\>G               c.2600_2604delinsA      311    Yes              59                     N             N
  5    M        11                 HyperCKemia                                                       IVS1-13T\>G               c.573C\>A               276    No               \-                     N             N
  6    F        45                 Proximal weakness LL                                              IVS1-13T\>G               c.1532C\>A              322    Yes              42                     N             N
  7    F        51                 Proximal weakness LL                                              IVS1-13T\>G               c.236_246del            240    Yes              47                     N             N
  8    M        66                 Axial + respiratory insufficiency                                 IVS1-13T\>G               c.1933G\>T              406    No               \-                     N             N
  9    F        59                 Proximal weakness LL                                              IVS1-13T\>G               c.1637A\>G              341    Yes              52                     N             N
  10   F        55                 Proximal weakness LL                                              IVS1-13T\>G               c.2173C\>T              359    Yes              48                     N             N
  11   M        42                 Proximal weakness LL + axial + respiratory insufficiency          IVS1-13T\>G               c.573C\>A               606    Yes              39                     N             Y
  12   F        31                 Proximal weakness UL and LL + respiratory insufficiency           IVS1-13T\>G               c.1637A\>G              391    Yes              24                     Y             Y
  13   F        46                 Proximal weakness LL                                              IVS1-13T\>G               C.1192dupC              396    Yes              39                     N             N
  14   M        47                 Proximal weakness LL + respiratory insufficiency                  c.2173C\>T                c.2173C\>T              508    Yes              45                     N             Y
  15   M        51                 Proximal weakness LL + respiratory insufficiency                  IVS1-13T\>G               c.1657C\>T              709    Yes              45                     N             Y
  16   F        51                 Proximal weakness UL and LL + respiratory insufficiency           IVS1-13T\>G               c.1657C\>T              458    Yes              46                     N             Y
  17   M        22                 HyperCKemia                                                       IVS1-13T\>G               c.1781G\>A              1268   No               \-                     N             N
  18   M        49                 HyperCKemia                                                       c.271G\>A                 c.2510G\>A              641    No               \-                     N             N
  19   M        14                 HyperCKemia                                                       IVS1-13T\>G               c.573C\>A               660    No               \-                     N             N
  20   F        65                 Proximal weakness LL + respiratory insufficiency                  c.1781G\>A                c.1194+5G\>A            68     Yes              64                     N             N
  21   F        35                 Proximal weakness LL                                              IVS1-13T\>G               c.1A\>T                 355    Yes              29                     N             N
  22   F        40                 Proximal weakness LL                                              IVS1-13T\>G               c.1889-1G\>A            831    No               \-                     N             Y
  23   F        52                 Proximal weakness LL + respiratory insufficiency                  c.1781G\>A                c.1194+5G\>A            907    Yes              45                     N             N
  24   M        64                 Proximal weakness UL + LL + axial + respiratory insufficiency     IVS1-13T\>G               c.2481+102_2646+31del   430    Yes              57                     N             Y
  25   M        8                  HyperCKemia                                                       IVS1-13T\>G               c.1889-1G\>A            1077   No               \-                     N             N
  26   F        57                 Proximal weakness LL + respiratory insufficiency                  IVS1-13T\>G               c.1447G\>T              394    Yes              55                     N             Y
  27   M        46                 Proximal weakness LL                                              IVS1-13T\>G               c.1532 C\>A             882    Yes              43                     N             Y
  28   M        51                 Proximal weakness LL                                              IVS1-13T\>G               c.1933G\>T              952    Yes              51                     N             Y
  29   M        51                 Proximal weakness LL                                              IVS1-13T\>G               c.1933G\>T              432    No               \-                     N             Y
  30   M        43                 Proximal weakness LL                                              IVS1-13T\>G               c.1408_1410delinsTTT    317    Yes              43                     N             N
  31   F        54                 Axial                                                             \*Not found               \*Not found             275    Yes              48                     N             N
  32   M        42                 Proximal weakness UL + LL                                         IVS1-13T\>G               c.655G\>A               886    No               \-                     N             N
  33   F        20                 HyperCKemia                                                       IVS1-13T\>G               c.1551+1G\>A            928    No               \-                     N             N
  34   M        50                 Proximal weakness LL                                              IVS1-13T\>G               c.1637A\>G              492    No               \-                     N             Y

Patient 31: Diagnosis was confirmed by enzymatic quantification in muscle biopsy and peripheral blood lymphocytes. No mutation was found in the GAA gene. F, female. M, male

10.1371/journal.pone.0163493.t002

###### Demographic, clinical and radiologic features of hyperCKemia and symptomatic Pompe patients.
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                                                     HyperCKemia (N = 7)   Symptomatic (n = 27)   Statistical significance
  -------------------------------------------------- --------------------- ---------------------- --------------------------
  Demographic characteristics                                                                     
  Age at study (y)                                   21.4 (+/-15.5)        50.1 (+/-8.9)          \<0.001
  Gender female                                      2/7 (28.6%)           16/27 (59.3%)          0.124\*
  Delay in diagnosis (y)                             6.1(+/- 5.1)          9 (+/- 7)              0.367
  Time of progression (y)                            NA                    15.5                   NA
  Strenght and functional scales                                                                  
  Total MRC score                                    119.5 (0.7)           96 (15.5)              \<0.001
  Myometry score (Nm)                                288.28 (137.3)        196.63 (136.1)         0.143
  Time to walk 10 meters (sec)                       3.22 (0.5)            7.40 (3.7)             0.006
  6 minutes walking test (meters)                    594 (75.6)            403.5 (147.1)          0.003
  Time climb up 4 steps (sec)                        1.5 (0.2)             4.7 (3.4)              0.002
  Time go down 4 steps (sec)                         1.4 (0.2)             3.7 (2.5)              0.022
  Time to up&go (sec)                                3.8 (1.5)             9.4 (8.5)              0.140
  Daily live activities and quality of live scales                                                
  Activlim                                           36 (6.3)              29.3 (5.9)             0.003
  SF-36 (%)                                                                                       0.002
  INQuol                                             14.4                  110.6                  \<0.001
  Laboratory, respiratory and cardiac assesments                                                  
  CVF seated (%)                                     95.7(12.2)            75.7(22.6)             0.049
  CVF lying (%)                                      82.3 (12.5)           64.4(27)               0.240
  CPKs (U/l)                                         911.5 (260.9)         523.8(236.6)           0.008
  Muscle MRI-T1w imaging                                                                          
  Total muscle MRI Score                             6 (6.8)               125.9 (46.7)           \<0.001
  Muscle MRI head/arms                               2.1                   25.3                   \<0.001
  Muscle MRI trunk                                   4.9                   13.7                   \<0.001
  Muscle MRI legs                                    0.5                   74.3                   \<0.001
  Muscle MRI-3 point Dixon imaging                                                                
  Thighs fat fraction (%)                            11.73                 38.17                  \<0.0001
  Paraspinal muscles fat fraction (%)                18.79                 65.07                  \<0.0001

The most common clinical complaint was muscle weakness involving lower limbs. Only 20% of patients had problems raising their arms. Twelve patients used aids for walking such as cane or stick, while two patients were wheelchair bound. Exertion dyspnea was present in 60% of patients and orthopnea was present in 28%. Thirteen of 27 symptomatic patients (48.1%) were on respiratory support; which was non-invasive and nocturnal in 12 patients and invasive in 1 patient.

Twenty-two of the 27 symptomatic patients were treated with ERT, while none of the hyperCKemia patients were under ERT. The mean age at which ERT was started was 45.7 +/- 9 years old. The mean time on ERT when the tests were performed was 4.4 +/- 1.03 years.

Analysis of muscle function {#sec013}
---------------------------

The MRC scale detected muscle weakness in all symptomatic patients. Hierarchical clustering analysis of the MRC scale scores showed that paraspinal, abdominal and proximal muscles of lower limbs were the weakest muscles ([Fig 1](#pone.0163493.g001){ref-type="fig"}). In general, hip extension was weaker than hip flexion and thigh adduction was weaker than thigh abduction. Mean muscle MRC score was 161.5 points (range 124--180). MRC score had a poor correlation with age at the time of the study (Spearman test, p:0.015; r = -0.414), with time from onset of the symptoms (Spearman test, p:0.018; r = -0.404) and with gender (Spearman test, p = 0.009, r: 0.441) and did not correlate with delay in the start of ERT ([Table 3](#pone.0163493.t003){ref-type="table"}). In contrast, MRC score had a good correlation with the results of most of muscle function tests used in clinical trials such as 6MWT or the time to climb up and down four stairs, and also with scales measuring daily live activities (Activlim) or muscle function (MFM-20). Correlation between MRC score and Quality of life scales was statistically significant, but correlation coefficient was poor. We also measured strength using hand-held myometry. The mean myometry score was 196.3 points (range 55--570). There was a good correlation between the total MRC score and the Myometry score (Spearman test, p = 0.001; r: 0.667). Myometry score correlated well with muscle function tests, but this correlation coefficient was lower than correlation coefficient obtained with MRC score ([Table 3](#pone.0163493.t003){ref-type="table"}).

![Distribution of muscle weakness in the cohort of AOPD participating in the study.\
The heatmap showed the MRC value for all muscles studied. Hip extension and flexion and trunk extension and flexion were the most weak impaired movements of the patients. In contrast, we did not observe distal weakness involving the lower or the upper limbs.](pone.0163493.g001){#pone.0163493.g001}

10.1371/journal.pone.0163493.t003

###### Correlation between MRC Score, Myometry Score, demographic data and muscle function tests.
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                                                     MRC Score   Myometry Score            
  -------------------------------------------------- ----------- ---------------- -------- --------
  Demographic data                                                                         
  Gender                                             0.009       0.441            0.01     0.553
  Age at MRI                                         0.015       -0.414           0.049    -0.351
  Time from onset of symptoms                        0.018       -0.404           0.012    -0.437
  Delay from onset to ERT                            0.158                        0.384    
  Functional tests                                                                         
  Time to walk 10 meters                             0.0001      0.803            0.0001   0.722
  6MWT                                               0.0001      0.708            0.0001   0.642
  Time to up&go                                      0.083       -0.322           0.487    -0.132
  Time to climb up 4 stairs                          0.0001      -0.810           0.0001   -0.630
  Time to go down 4 stairs                           0.0001      -0.770           0.0001   -0.664
  MFM-20                                             0.0001      0.803            0.0001   0.722
  Daily live activities and Quality of life scales                                         
  Activlim                                           0.0001      0.860            0.0001   0.726
  SF-36                                              0.017       0.448            0.002    0.579
  INQoL                                              0.001       -0.587           0.001    -0.633
  Respiratory tests                                                                        
  CVF seated                                         0.012       0.454            0.469    0.140
  CVF lying                                          0.05        0.498            0.666    0.121
  MIP                                                0.246       -0.308           0.254    -0.314
  MEP                                                0.149       -0.392           0.670    0.125

Table 3 shows correlation between MRC Score and myometry score with demographic data, muscle function tests and daily live activities.

Muscle MRI analysis: T1w imaging and pattern description {#sec014}
--------------------------------------------------------

We performed a hierarchical clustering analysis of values obtained from the quantification of T1w muscle MRI and visualized these data using heatmaps ([Fig 2](#pone.0163493.g002){ref-type="fig"}). Our analysis showed predominant involvement of paraspinal muscles, abdominal muscles, tongue, *subscapularis* and *latissimus dorsi* in head and trunk. Head muscles (except tongue), upper limbs and periscapular muscles (except *subscapularis*) were not generally involved. In lower limbs, *glutei* muscles, *psoas*, *illiacus* and posterior muscles of the thighs (*semitendinosus*, *semimembranosus*, *adductor major* and *longus*, and both heads of *biceps*) were predominantly involved. *Glutei minor* and *medius* were more involved than *glutei maximus*. *Vastus intermedius* was the most commonly involved quadriceps muscle, while *rectus femoris* was rarely involved. In contrast, *sartorius* and *gracillis muscles* and lower legs muscles were commonly spared ([Fig 2](#pone.0163493.g002){ref-type="fig"}). We show some examples of muscle involvement in [Fig 3](#pone.0163493.g003){ref-type="fig"}.

![Representation of score of muscle infiltration observed in T1 imaging in each muscle of every patient by heatmaps.\
(A) Heatmap including muscles of the head, upper limbs and trunk. (B) Heatmap including muscles of the pelvis and lower limbs. In each heatmap, patients (rows) are ordered according to hierarchical clustering with increasing grading in infiltration severity from the top to the bottom. Muscles (columns) are ordered according to dendrogram (upper part of the figures). The score of a muscle in a patient is indicated by the colour of the square in the interaction between the patient and that muscle. The darker the square, the more intense the fatty infiltration of that muscle is.](pone.0163493.g002){#pone.0163493.g002}

![T1w Muscle MRI of patients with Pompe disease.\
We observed mild fatty infiltration in muscles of hyperCKemia patients: Tongue (Tin A), paraspinal muscles (Ps in B), lateral abdominal muscles (Ab in B) and *rectus abdominis* (RA in C) and in *adductor major* muscles (AM in D). The fatty infiltration in symptomatic patients was more evident (E-L). The muscles more commonly involved were tongue (T in E), *subscapularis* (Sc in F), *latissimus dorsi* (LD in G), the abdominal (Ab in H) and paraspinal muscles (Ps in H), the *Gluteus minor* (GMn in I), *medius* (GMe in J) and *maximus* (GMa in J), the muscles of the pelvic floor such as the *Externus Obturator* (Obt. Ext. in K), the posterior muscles of the thighs (Post in L), and the vasti muscles including *vastus intermedius* (VI in M) and *vastus lateralis* (VL in M). We observed involvement of *rectus femoris* and *gracillis* in advanced patients (RF and Gra in N). Muscles of the lower legs were commonly spared (O).](pone.0163493.g003){#pone.0163493.g003}

We observed subtle changes in 4 of the 7 pre-symptomatic patients ([Fig 2](#pone.0163493.g002){ref-type="fig"}). Mild fatty infiltration (score = 1) was observed in paraspinal muscles (*multifidus*, *longisimus*, *iliocostalis*), abdominal muscles (*rectus abdominis*, *obliquus internus*, *obliquus externus*, *transversus abdominalis*), tongue, and *adductor major* muscles.

Muscle MRI analysis: 3-point Dixon imaging. {#sec015}
-------------------------------------------

We analyzed twelve muscles of the thighs and four muscles of the trunk. [Fig 4A](#pone.0163493.g004){ref-type="fig"} summarizes the results, showing significant differences in fatty infiltration of muscles between symptomatic and hyperCKemia patients (Mann-Whitney U test, p\<0.05). [S1 Fig](#pone.0163493.s001){ref-type="supplementary-material"} shows an example of a 3-point Dixon analysis of thighs. The degree of muscle involvement in symptomatic patients varied from severe, as in *Adductor Major* (median fat fraction 78.05%) to mild involvement as in *Rectus femoris* (median fat fraction 13.46%) ([S1 Table](#pone.0163493.s003){ref-type="supplementary-material"}). Fatty substitution of paraspinal muscles (*multifidus*, *longisimus* and *illiocostalis*) was very high in symptomatic patients, reaching more than 80% in 19/27 symptomatic patients, and was also detectable in hyperCKemia patients (median fat fraction of 22.26%). There was a strong correlation between Mercuri scores detected using T1w imaging and fat fraction analyzed using 3-point Dixon images ([Fig 4D](#pone.0163493.g004){ref-type="fig"}).

![Analysis of fatty infiltration in muscle MRIs.\
(A) We observed significant differences in the percentage of fatty infiltration quantified using 3-point Dixon technique in most of the muscles between symptomatic (red bars) and hyperckemia patients (green bars). We compared both groups using the Student T test (single asterisk for differences with p\<0.05 and double asterisk for differences with p\<0.01). (B) Fat-fraction maps of the right thigh in a hyperckemia and a symptomatic AOPD patient. We show the quantification of the fatty involvement of posterior muscles of the thighs using the mean Mercuri Score and the mean 3 point Dixon score (*Semitendinosus*, *Semimembranosus*, *Biceps Long Head and Biceps Short Head)*. Pompe 14 patients (hyperckemia patient) had higher strength in knee flexion measured with the myometer than patient 1 (symptomatic patient). We observed predominant fatty infiltration in the posterior muscles of the thighs producing decreased strength in the knee flexion test. (C) There was a strong correlation between knee flexion strength and the degree of muscle fatty infiltration calculated both using 3-point Dixon (left) and the Mercuri scale (right). Green dots showed values of hyperckemia patients, while red ones represent values of symptomatic patients. (D) We found a strong correlation between 3 point Dixon analysis and Mercuri score. We have represented the correlation between the quantification of fat infiltration using the mean Mercuri score and the mean 3-point Dixon score of the posterior thigh muscles (*Semitendinosus*, *Semimembranosus*, *Biceps Long Head and Biceps Short Head*). RF: *rectus femoris*; VL: *vastus laterallis*; VM: *vastus medialis*; VI: *vastus intermedius*; AM: *adductor major*; AL: *adductor longus*; BSH: *biceps short head*; BLH: *biceps long head*; ST: *semitendinosus*; SM: *semimembranosus*; SA: *sartorius*; GR: *gracillis*; MU: *multifidus*; LO: *longissimus*; IL: *iliocostalis*; QU: *quadratus femoris*; PS: *psoas*; ABD: lateral abdominal muscles; RA: *rectus abdominis*.](pone.0163493.g004){#pone.0163493.g004}

Correlation between muscle function tests and muscle MRI {#sec016}
--------------------------------------------------------

Correlations between myometry measures and fat infiltration in appropriately tested muscles were similar for 3-point Dixon and for T1w imaging ([S2 Table](#pone.0163493.s004){ref-type="supplementary-material"}). For example, correlation between knee flexion strength and "hamstring average fat fraction" (the average of fatty infiltration in *semimembranosus*, *semitendinosus*, *biceps long* and *short head* muscles) for 3-point Dixon imaging was ρ = -0.70, while for T1w imaging, was r = -0.649 ([Fig 4D](#pone.0163493.g004){ref-type="fig"}).

We developed a muscle MRI-T1w score that was the sum of values of the Mercuri scale for each muscle. The mean MRI score was 6 (range: 0 to 15 points) in hyperCKemia patients and 125.9 (range: 39 to 210 points) in symptomatic patients ([Table 2](#pone.0163493.t002){ref-type="table"}). These differences reached statistical significance (Mann-Whitney U, p\<0.001). We found strong correlation between muscle MRI-T1w score and most of the functional muscle tests, such as MRC score, 6MWT, MFM-20 or Activlim scale ([Table 4](#pone.0163493.t004){ref-type="table"}). In contrast, we did not find a good correlation with respiratory tests results or quality of life scales (SF-36 and INQoL). [Fig 5](#pone.0163493.g005){ref-type="fig"} shows 3 examples of correlation between Muscle MRI and functional tests.

![Correlation between Muscle MRI and Functional scales.\
Patient 30 is a 43 years old man with mild infiltration of pelvic and lower limbs muscles with minor functional impairment. Patient 22 is a 40 years old lady with moderate involvement of trunk, pelvic and thighs muscles. She was able to perform most of her daily live activities with no major problems but her clinical examination showed moderate weakness of pelvic muscles. Patient 2 is a 48 years old lady with a severe involvement of muscle producing severe weakness and notably impairing her daily live activities.](pone.0163493.g005){#pone.0163493.g005}

10.1371/journal.pone.0163493.t004

###### Comparison among MRI score and 3-point Dixon correlations with demographic data and muscle function tests.
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                                                     T1w-MRI Score   3-point Dixon (Average Thigh)            
  -------------------------------------------------- --------------- ------------------------------- -------- --------
  Demographic data                                                                                            
  Gender                                             0.069           -0.315                          0.019    -0.456
  Age at MRI                                         0.055           0.381                           0.022    0.391
  Time from onset of symptoms                        0.257           0.231                           0.043    0.349
  Delay from onset to ERT                            0.421           -0.224                          0.498    -0.152
  Functional tests                                                                                            
  Myometry Score                                     0.001           -0.560                          0.0001   -0.633
  6MWT                                               0.001           -0.610                          0.0001   -0.764
  Time to up&go                                      0.097           0.308                           0.006    0.515
  Time to climb up 4 stairs                          0.0001          -0.782                          0.0001   0.858
  Time to go down 4 stairs                           0.0001          -0.737                          0.0001   0.810
  MFM-20                                             0.0001          0.693                           0.0001   -0.681
  Daily live activities and Quality of life scales                                                            
  Activlim                                           0.0001          0.785                           0.0001   -0.754
  Respiratory tests                                                                                           
  FVC seated                                         0.035           -0.386                          0.018    -0.469
  FVC lying                                          0.08            -0.450                          0.055    -0.544
  PIM                                                0.356           0.247                           0.40     0.253
  PEM                                                0.541           -0.171                          0.6      -0.16

We also found strong correlation between the average fat fraction of thigh measured using 3-point Dixon imaging and functional scales ([Table 4](#pone.0163493.t004){ref-type="table"}). In most of the cases, correlation coefficients were higher for 3-point Dixon studies than for T1w imaging. For instance, the correlation coefficient between 6MWT (main test used in clinical trials) and 3-point Dixon tests was ρ = -0.764 while it was lower for T1w imaging, r = -0.610. There was no correlation between 3-point Dixon studies and results of respiratory studies.

We analyzed the group of hyperCKemia patients in detail. We found mild changes in muscle MRI in four out of seven cases using T1w imaging that were statistically significant (Mann-Whitney U test, p = 0.008). HyperCKemia patients with changes in MRI were older than 20 years old, whereas patients with no changes were younger than 15 years old. 3-point Dixon analysis showed statistically significant differences in the amount of muscle fatty infiltration of the paraspinal muscles in hyperCKemia patients older than 20 years when they were compared with patients younger than 15 years old ([Table 5](#pone.0163493.t005){ref-type="table"}). In contrast, functional scales were similar in both groups.

10.1371/journal.pone.0163493.t005

###### Comparison between presymptomatic patients with hyperckemia depending on the results of the MRI.
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                                                      Normal MRI (n = 3))   Abnormal MRI (n = 4))   Mann-Whitney
  --------------------------------------------------- --------------------- ----------------------- --------------
  Age (y)                                             11                    29.2                    0.073
  MRC Score                                           180                   179.2                   0.243
  Myometry Score (Nm)                                 261.24                308.49                  0.695
  6MWT (min)                                          616                   577                     0.572
  Time to walk 10 meters (sec)                        3.0                   3.3                     0.571
  Time to climb up 4 stairs (sec)                     1.4                   1.5                     0.677
  Time to go down 4 stairs (sec)                      1.3                   1.5                     0.455
  Time to up&go (sec)                                 4.8                   3.1                     0.204
  MFM-20                                              57.6                  59.2                    0.471
  Activlim                                            36                    36                      1
  T1w-MRI Score                                       0                     10.5                    0.008
  3-point Dixon Fat fraction Thighs (%)               11.93                 11.58                   0.865
  3-point Dixon Fat fraction Paraspinal muscles (%)   13.54                 33.43                   0.039

Discussion {#sec017}
==========

In the present paper we demonstrate that muscle MRI is a useful tool for the study of patients with AOPD for several reasons. Muscle MRI efficiently identifies a group of atrophic muscles that corresponds to the weakest muscles in clinical examination. Muscle MRI has a good correlation with results of the functional muscle scales commonly used in clinical trials. Additionally, muscle MRI has sensitivity to detect early fat infiltration in patients with hyperCKemia before functional scales are impaired. Based on our results, muscle MRI is a acceptable tool to investigate muscle function status in patients with AOPD.

MRI imaging is progressively gaining widespread use to study patients with muscle diseases\[[@pone.0163493.ref014]\]. There are sequences available to study several aspects of muscle structure. Carlier et al showed the striking utility of using whole-body T1w imaging in a group of twenty AOPD patients, revealing bright signals as indicators of fat replacement in some specific muscles\[[@pone.0163493.ref021]\]. This technique facilitates pattern recognition when diagnosis is not clear \[[@pone.0163493.ref022]\]. However, quantification of fatty infiltration using T1w imaging is based usually in visual semiquantitative scales that are observer dependent. On the other hand, analysis of 3-point Dixon images is performed using software that quantifies the exact amount of fat per pixel. Thus, 3-point Dixon is more accurate than T1w imaging to detect slight changes in fatty infiltration. For this reason, 3-point Dixon could be potentially useful in clinical trials of patients with AOPD, in which fatty infiltration slowly progresses over time.

Nevertheless, to consider muscle MRI findings as a reliable outcome measure, it should also correlate with relevant patient function tests\[[@pone.0163493.ref023]\]. We show strong correlations between muscle MRI results and several functional scales commonly used in clinical trials such as MRC, time to walk 10 meters or the Activlim scale. We detected a significant correlation between muscle strength measured using hand held myometry and muscle fat fraction. Accordingly MRI provides evidence of muscle damage that correlate strongly with muscle strength and function that are independent of participant effort. This fact is especially important in patients with AOPD in whom 6 MWT has been used as the main functional test to analyze response to treatment. 6MWT is not only dependent on muscle strength, but is also influenced by many other factors such as dyspnea and muscle pain, therefore in our opinion, it analyzes general endurance. In fact, we have found a good correlation between muscle MRI and 6MWT. Moreover, the correlation between muscle MRI and muscle strength was strong. Muscle groups that were found atrophic in muscle MRI were the ones weak in MRC study. Heatmaps analyzing MRC ([Fig 1](#pone.0163493.g001){ref-type="fig"}) and muscle MRI are practically overlapping ([Fig 2](#pone.0163493.g002){ref-type="fig"}). Based on our results, muscle MRI offers a valid and consistent surrogate measure of muscle function. The group of Hovarth studied 7 Pompe patients and 11 controls, using whole-body proton-density fat-fraction imaging\[[@pone.0163493.ref024]\]. They reported a great sensitivity of MRI to detect subtle changes in skeletal muscles and a good correlation between muscle MRI results and muscle strength analyzed using MRC scale. Our study, which contains a larger number of patients, a more detailed physical examination, a comparison between quantitative and qualitative MRI sequences, and a shorter MRI protocol time (no more than 45 min), confirms their results.

Muscle MRI is also able to identify early changes in muscle signal of several neuromuscular disorders. We observed signs of muscle fatty infiltration in 4 out of 7 patients without any clinical symptom of muscle weakness. Clinical examination, functional and respiratory tests were all normal in these patients. In contrast, muscle MRI already revealed subtle changes, preferentially involving paraspinal and abdominal muscles, suggesting that the process of muscle degeneration had started. A recent retrospective study in a small cohort of AOPD patients analyzing muscle MRI of lower limbs in four asymptomatic patients showed a remarkable increase in fat infiltration of *Adductor magnus* muscle and mild changes in the remaining thigh muscles in one pre-symptomatic patient, suggesting that progressive fatty muscle infiltration starts before clinical manifestations\[[@pone.0163493.ref021]\]. However, the authors only used T1w imaging to determine mean gray values, which is not a quantitative technique. We have used 3-point Dixon sequences which calculate the exact percentage of fat in every muscle\[[@pone.0163493.ref025]\]. Moreover, we have analyzed muscle function in detail using several different tests demonstrating the lack of symptoms in patients with isolated hyperCKemia and therefore strengthening our results. In our opinion, detection of a progressive increase in the amount of fatty infiltration in skeletal muscles could potentially be taken into account before deciding to start ERT treatment in a patient with clinically asymptomatic AOPD. Although it is not know how much fatty infiltration in a single muscle is needed to produce weakness, it seems clear that the process of muscle fatty degeneration is not reversible once the treatment is started\[[@pone.0163493.ref026], [@pone.0163493.ref027]\]. Based on our results, it makes sense to follow-up AOPD patients with repeated muscle MRIs, especially those with asymptomatic hyperCKemia. Analysis of paraspinal and abdominal area is crucial to detect changes and to determine whether fatty involvement of muscles progress\[[@pone.0163493.ref028]\]. We have already described the early involvement of paraspinal muscles in AOPD patients, which can sometimes present as a pure axial myopathy\[[@pone.0163493.ref028]\]. In this sense, 3-point Dixon imaging technique has emerged as a powerful tool, superior to T1w imaging, to detect subtle changes in percentage of muscle fatty infiltration in skeletal muscles\[[@pone.0163493.ref029]\]. Other quantitative sequences, such as quantitative T2-mapping, also showed a better profile than T1-weighted imaging to determine minimal changes in AOPD progression\[[@pone.0163493.ref030]\]. Although our aim was not to analyze disease progression, those results reinforce the need to improve our knowledge and use of new quantitative techniques.

In the last years several groups have started using quantitative MRI sequences to follow-up AOPD patients. However, these new quantitative techniques have some drawbacks: they are not available in many of the medical centers, they need specific software for quantification and the acquisition and analysis of the images consume a lot of time. In order to surpass these limitations, some authors have quantified fat tissue in skeletal muscles of T1w images using imaging software. For example, the group of Dr. Pichiechio followed-up 9 AOPD patients for six-months and the group of Dr. Kley analyzed muscle MRI of 7 AOPD using this technology\[[@pone.0163493.ref031], [@pone.0163493.ref032]\]. Although they were able to identify changes in fat tissue present in the muscles, it has reported than 3-point Dixon is more precise and reliable than T1w analysis for evaluation of fat fractions in longitudinal follow-up studies of patients with neuromuscular disorders\[[@pone.0163493.ref029]\]. We are currently conducting a prospective study of a large cohort of AOPD patients using 3-point Dixon as a tool in patient follow-up. We hope this new study will further support the usefulness of MRI for routine clinical practice.

In conclusion, muscle MRI is a reliable, valid and surrogate biomarker of muscle function in patients with AOPD. Muscle MRI is not only useful for diagnosis but also may be useful to predict muscle function in these patients. Furthermore, muscle MRI visualizes fatty muscle infiltration in asymptomatic Pompe patients before functional tests are impaired and potentially help to decide when ERT treatment should be started. Based on our observations, we consider muscle MRI could be used as a complementary test in clinical trials and in daily clinics of patients with AOPD.
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###### Examples of Fat fraction estimation.

\(A\) Muscles of the thighs can be clearly identified in a single slice. (B) Selection of the region of interest (ROI) in the *vastus laterallis* muscle for the analysis of fat fraction that in this case is of 23.1%. (C) Paraspinal muscles can be identified in a single slice. (D) Selection of the region of interest (ROI) in the *multifidus* muscle for the analysis of fat fraction that in this case is of 21%.

(TIF)

###### 

Click here for additional data file.

###### Muscles studied using Fischer modified Mercuri Scale and 3 point Dixon.

(DOC)

###### 

Click here for additional data file.

###### Quantification of fatty muscle infiltration using 3-point Dixon imaging.

Quantification of fatty muscle infiltration in muscles of thighs and trunk in symptomatic AOPD patients and patients with hyperckemia only. Student T test was used to compare both groups of patients. P values lower than 0.05 were considered significant.

(DOCX)

###### 

Click here for additional data file.

###### Comparison of the correlation between quantification of fatty involvement analyzed using T1 imaging and 3-point Dixon with muscle strength in appropriately tested muscles.

We correlated the strength of the thighs muscles with the degree of fatty infiltration in muscles analyzed using T1w and 3-point Dixon imaging. We correlated hip flexion with fatty infiltration of psoas muscle, hip adduction with an average of fatty infiltration of *adductor longus* and major, knee extension with the average of fatty infiltration of *rectus femoris*, *vastus medialis*, *vastus intermedius* and *vastus lateralis*; and knee flexion with the average of fatty infiltration of *semitendinosus*, *semimembranosus*, *biceps long head* and *biceps short head*.

(DOCX)

###### 

Click here for additional data file.
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